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OBJECTIVES: Nationwide organized breast cancer program
was introduced in 2002 in Hungary. The purpose of this study
is to analyze the effect of breast cancer screening program on the
number and ration of breast surgeries. METHODS: The data
derived from the ﬁnancial database of the National Health Insur-
ance Fund Administration. We identiﬁed the patients with ICD
codes and Diagnosis Related Groups (DRG). The study covers
the ﬁve-year period between 2000–2004. We deﬁned total mas-
tectomy as the removal of preferably all breast tissue. Subtotal
mastectomy (e.g. quadrantectomy) is deﬁned as breast conserv-
ing surgery. We carried out the detailed analysis for the years
2000–2001, without nationwide organized screening program,
and for the years 2002–2003 (ﬁrst screening round) after the
implementation of nationwide organized breast cancer screening
program. RESULTS: The total number of breast surgeries was
7306 in 2000 and 7549 in 2001. After the introduction of the
nation wide organized breast cancer screening program the total
number of breast surgeries increased to 8531 in 2002 and 9140
in 2003. Compared to the values of 2000 as 100%, the number
of total mastectomies increased 107.8% in 2002 and 109.6%,
while the number of subtotal mastectomies increased much
more: 120.3% in 2002 and 127.4% in 2003. The ratio of total
and subtotal mastectomies in 2000 was 46.2% versus 53.8%.
By 2004 the proportion of total mastectomies decreased to 
40.0% and the proportion of subtotal mastectomies increased to
60%. The number of surgeries because of benign cases has also
increased. CONCLUSIONS: The introduction of organized
nationwide breast cancer screening program increased the total
number of breast surgeries. Within the total number of breast
surgeries decreased the proportion of total and increased the pro-
portion of subtotal or breast conserving mastectomies.
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OBJECTIVE: The risk cut off to recommend BRCA 1 and 2 gene
testing varies from 10% for the American Society of Clinical
Oncology to 20% in European countries. Considering pts with
a previous diagnosis of breast cancer, we aimed to establish a
risk cut off policy for genetic testing at our service, in terms of
direct costs. A total of 130pts with a previous breast cancer, in
routine follow-up, received invitation to schedule consultation in
the hereditary breast cancer unit. METHODS: Of these, 77
patients, were interviewed by a multidisciplinary team, and had
their risk assessed based on family pedigree and conﬁrmed
pathological information (Frank Ts et al, JCO 20:1480–1490,
2002). Direct costs of genetic testing were considered as the sum
of costs of reagents, permanent equipment and personnel
excluded. Prices in reais were converted to dolar (2.3 reais per
dolar). RESULTS: Our survey have shown that 3 women in 77
surveyed were to be tested with a risk cut off established in 20%
as compared to 16 with a risk assessment of >10%. Consider-
ing the offspring, screening those women would beneﬁt 162 and
21other women, respectively, at 10% and 20% cut off. The total
direct costs of gene testing would be $31,023.86 at 10% and
$5816.97 at 20%. In case we consider all ﬁrst degree women rel-
atives as beneﬁciaries, independent of the result being positive or
negative for BRCA mutation, cost effectiveness (CE) ratio of
$191.50 per individual beneﬁted at 10% and $276.99/beneﬁ-
ciary at 20%. CONCLUSION: A 20% cut off for genetic testing
in this population with breast cancer seems very strict, since the
number of women indicated for genetic testing was far bellow
the 5% expected in breast cancer population. Considering the
other family members, the higher cost associated with 10% cut
off could beneﬁt more women.
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OBJECTIVES: To better understand the real-world dosing pat-
terns of epoetin alfa (EPO) and darbepoetin alfa (DARB) in
patients with cancer receiving chemotherapy, a large retrospec-
tive, observational study was undertaken to analyze dosing pat-
terns and associated costs of patients treated with EPO and
DARB in the outpatient setting. METHODS: Adult patients who
had cancer and were receiving chemotherapy, had ≥2 EPO or
DARB claims, and were newly initiated on erythropoiesis stim-
ulating therapy (EST) between April 2003 and February 2005
were identiﬁed from a nationwide sample of outpatient medical
claims from hospital clinics and ofﬁce practices. EPO and DARB
use was identiﬁed via HCPCS codes in medical claims with dose
calculated using billed units. Average treatment duration, dosing
frequency, mean cumulative dose, and total EST costs (using
2005 wholesale acquisition prices) were studied. RESULTS: A
total of 1405 EPO and 1087 DARB patients met the inclusion
criteria. Mean age (years; EPO 63 ± 13; DARB 62 ± 12) was
similar between groups, with more women in the DARB group
(EPO 62%; DARB 71%, p < 0.05). Weekly and extended dosing
(≥Q2W) frequencies were utilized in patients receiving EPO
(QW: 65%, Q2W: 29%, ≥Q3W: 6%) and DARB (QW: 11%,
Q2W: 61%, ≥Q3W: 28%). Mean treatment duration was 54 ±
51 days for EPO and 52 ± 46 days for DARB. Mean cumulative
dose for EPO and DARB was 296,070 IU and 1022mcg corre-
sponding to a dose only ratio of 290 :1 (units EPO: mcg DARB)
and total EST costs of $3603 and $4456, respectively. CON-
CLUSION: In this large observational study, DARB treatment
costs were substantially higher (24%) than EPO treatment costs.
In addition, extended EPO and DARB dosing was common
among patients with cancer receiving chemotherapy.
CANCER—Methods and Concepts
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OBJECTIVES: To assess inter-rater agreement for Health Utili-
ties Index (HUI) Mark 3 (HUI3) measurements of patients
